A review on biomass-derived levulinic acid for application in drug synthesis

doi:10.1080/07388551.2021.1939261

	A review on biomass-derived levulinic acid for application in drug synthesis
	Zhang, Mingyue 2,3; Wang, Nan 1,2; Liu, Jianguo 2,3; Wang, Chenguang 2,3; Xu, Ying 2,3; Ma, Longlong 2,3
刊名	CRITICAL REVIEWS IN BIOTECHNOLOGY
	2021-06-10
页码	34
关键词	Biomass levulinic acid drug linkers medicinal materials reducing cost
ISSN号	0738-8551
DOI	10.1080/07388551.2021.1939261
通讯作者	Liu, Jianguo(liujg@ms.giec.ac.cn) ; Ma, Longlong(mall@ms.giec.ac.cn)
英文摘要	Levulinic acid (LEV) has been identified as a key building block chemical produced entirely from biomass. Its derivatives can be used to synthesize a variety of value-added chemicals, such as 2-butanone, 2-methyltetrahydrofuran, and so on. LEV has carbonyl and carboxyl functional groups, which makes it flexible, diverse, and unique during drug synthesis. It also reduces the cost of drug synthesis and makes the reaction cleaner and, not the least, has untapped potential in the field of medicine. This article reviews the application of LEV in cancer treatment, medical materials, and other medical fields. Overall, LEV can be used in the following ways: (1) Used as a raw material to directly synthesize drugs; (2) Used to synthesize related derivatives, which can be more specifically used in drug synthesis, and derivatives can achieve the corresponding release of drugs, such as paclitaxel (PTX)- LEV, polymer-betulinic acid (BA)-LEV after amidation; (3) It can modify chemical reagents or act as linkers to connect pharmaceutical reagents with carriers to form pharmaceutical intermediates, a pharmaceutical intermediate skeleton, and so on. (4) It can acylate and esterify to form: acetylpropionate and levulinyl, the indole, pyridazine, and other medicinally active functional groups can be synthesized by a long chain, which can reduce the cost of drug synthesis and simplify the tedious synthesis steps. (5) To form the protective group of levulinic acid, the hydroxyl or carboxyl position is first protected, and then the protective group is removed after the corresponding reaction, in order to participate in drug synthesis.
资助项目	National Key R&D Program of China[2018YFB1501500] ; National Natural Science Foundation of China[51976225] ; DNL Cooperation Fund ; CAS[DNL201916]
WOS关键词	ONE-POT SYNTHESIS ; 5-AMINOLEVULINIC ACID ; BIOLOGICAL EVALUATION ; DERIVATIVES ; DELIVERY ; POLYMER ; DESIGN ; NANOPARTICLES ; INHIBITORS ; DOCETAXEL
WOS研究方向	Biotechnology & Applied Microbiology
语种	英语
出版者	TAYLOR & FRANCIS LTD
WOS记录号	WOS:000671727500001
资助机构	National Key R&D Program of China ; National Natural Science Foundation of China ; DNL Cooperation Fund ; CAS
内容类型	期刊论文
源URL	[http://ir.giec.ac.cn/handle/344007/33460]
专题	中国科学院广州能源研究所
通讯作者	Liu, Jianguo; Ma, Longlong
作者单位	1.Tianjin Univ, Sch Environm Sci & Engn, Tianjin, Peoples R China 2.Chinese Acad Sci, Guangzhou Inst Energy Convers, Key Lab Renewable Energy, Guangzhou 510640, Peoples R China 3.Univ Chinese Acad Sci, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Zhang, Mingyue,Wang, Nan,Liu, Jianguo,et al. A review on biomass-derived levulinic acid for application in drug synthesis[J]. CRITICAL REVIEWS IN BIOTECHNOLOGY,2021:34.
APA	Zhang, Mingyue,Wang, Nan,Liu, Jianguo,Wang, Chenguang,Xu, Ying,&Ma, Longlong.(2021).A review on biomass-derived levulinic acid for application in drug synthesis.CRITICAL REVIEWS IN BIOTECHNOLOGY,34.
MLA	Zhang, Mingyue,et al."A review on biomass-derived levulinic acid for application in drug synthesis".CRITICAL REVIEWS IN BIOTECHNOLOGY (2021):34.